<?xml version="1.0" encoding="UTF-8"?>
<GoldLabel drug="VALIUM">
  <Text>
    <Section id="S1" name="adverse reactions">    ADVERSE REACTIONS  

  Side effects most commonly reported were drowsiness, fatigue, muscle weakness, and ataxia. The following have also been reported:

     Central Nervous System:  

  confusion, depression, dysarthria, headache, slurred speech, tremor, vertigo

     Gastrointestinal System:  

  constipation, nausea, gastrointestinal disturbances

     Special Senses:  

  blurred vision, diplopia, dizziness

     Cardiovascular System:  

  hypotension

     Psychiatric and Paradoxical Reactions:  

  stimulation, restlessness, acute hyperexcited states, anxiety, agitation, aggressiveness, irritability, rage, hallucinations, psychoses, delusions, increased muscle spasticity, insomnia, sleep disturbances, and nightmares. Inappropriate behavior and other adverse behavioral effects have been reported when using benzodiazepines. Should these occur, use of the drug should be discontinued. They are more likely to occur in children and in the elderly.

     Urogenital System:  

  incontinence, changes in libido, urinary retention

     Skin and Appendages:  

  skin reactions

     Laboratories:  

  elevated transaminases and alkaline phosphatase

     Other:  

  changes in salivation, including dry mouth, hypersalivation

 Antegrade amnesia may occur using therapeutic dosages, the risk increasing at higher dosages. Amnestic effects may be associated with inappropriate behavior.

 Minor changes in EEG patterns, usually low-voltage fast activity, have been observed in patients during and after Valium therapy and are of no known significance.

 Because of isolated reports of neutropenia and jaundice, periodic blood counts and liver function tests are advisable during long-term therapy.

   Postmarketing Experience

  Injury, Poisoning and Procedural Complications

  There have been reports of falls and fractures in benzodiazepine users. The risk is increased in those taking concomitant sedatives (including alcohol), and in the elderly.

</Section>
    <Section id="S2" name="boxed warnings">

    BOXED WARNING: WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS

    WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS  

  Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death (see     Drug Interactions    ).

 *  Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. 
 *  Limit dosages and durations to the minimum required. 
 *  Follow patients for signs and symptoms of respiratory depression and sedation. 

</Section>
    <Section id="S3" name="precautions">   PRECAUTIONS

   General

  If Valium is to be combined with other psychotropic agents or anticonvulsant drugs, careful consideration should be given to the pharmacology of the agents to be employed - particularly with known compounds that may potentiate the action of diazepam, such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants (see  Drug Interactions  ).

 The usual precautions are indicated for severely depressed patients or those in whom there is any evidence of latent depression or anxiety associated with depression, particularly the recognition that suicidal tendencies may be present and protective measures may be necessary.

 Psychiatric and paradoxical reactions are known to occur when using benzodiazepines (see  ADVERSE REACTIONS  ). Should this occur, use of the drug should be discontinued. These reactions are more likely to occur in children and the elderly.

 A lower dose is recommended for patients with chronic respiratory insufficiency, due to the risk of respiratory depression.

 Benzodiazepines should be used with extreme caution in patients with a history of alcohol or drug abuse (see  DRUG ABUSE AND DEPENDENCE  ).

 In debilitated patients, it is recommended that the dosage be limited to the smallest effective amount to preclude the development of ataxia or oversedation (2 mg to 2.5 mg once or twice daily, initially, to be increased gradually as needed and tolerated).

 Some loss of response to the effects of benzodiazepines may develop after repeated use of Valium for a prolonged time.

    Information For Patients

  To assure the safe and effective use of benzodiazepines, patients should be informed that, since benzodiazepines may produce psychological and physical dependence, it is advisable that they consult with their physician before either increasing the dose or abruptly discontinuing this drug. The risk of dependence increases with duration of treatment; it is also greater in patients with a history of alcohol or drug abuse.

 Patients should be advised against the simultaneous ingestion of alcohol and other CNS-depressant drugs during Valium therapy. As is true of most CNS-acting drugs, patients receiving Valium should be cautioned against engaging in hazardous occupations requiring complete mental alertness, such as operating machinery or driving a motor vehicle.

     Drug Interactions  

   Opioids

  The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAAsites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation.

    Centrally Acting Agents

  If Valium is to be combined with other centrally acting agents careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants.

    Alcohol

  Concomitant use with alcohol is not recommended due to enhancement of the sedative effect.

    Antacids

  Diazepam peak concentrations are 30% lower when antacids are administered concurrently. However, there is no effect on the extent of absorption. The lower peak concentrations appear due to a slower rate of absorption, with the time required to achieve peak concentrations on average 20 - 25 minutes greater in the presence of antacids. However, this difference was not statistically significant.

    Compounds Which Inhibit Certain Hepatic Enzymes

  There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19). Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation. At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.

    Phenytoin

  There have also been reports that the metabolic elimination of phenytoin is decreased by diazepam.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

  In studies in which mice and rats were administered diazepam in the diet at a dose of 75 mg/kg/day (approximately 6 and 12 times, respectively, the maximum recommended human dose [MRHD=1 mg/kg/day] on a mg/m  2  basis) for 80 and 104 weeks, respectively, an increased incidence of liver tumors was observed in males of both species. The data currently available are inadequate to determine the mutagenic potential of diazepam. Reproduction studies in rats showed decreases in the number of pregnancies and in the number of surviving offspring following administration of an oral dose of 100 mg/kg/day (approximately 16 times the MRHD on a mg/m  2  basis) prior to and during mating and throughout gestation and lactation. No adverse effects on fertility or offspring viability were noted at a dose of 80 mg/kg/day (approximately 13 times the MRHD on a mg/m  2  basis).

     Pregnancy  

   Category D  (see  WARNINGS: Pregnancy  ).

     Pediatric Use  

  Safety and effectiveness in pediatric patients below the age of 6 months have not been established.

     Geriatric Use  

  In elderly patients, it is recommended that the dosage be limited to the smallest effective amount to preclude the development of ataxia or oversedation (2 mg to 2.5 mg once or twice daily, initially to be increased gradually as needed and tolerated).

 Extensive accumulation of diazepam and its major metabolite, desmethyldiazepam, has been noted following chronic administration of diazepam in healthy elderly male subjects. Metabolites of this drug are known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

     Hepatic Insufficiency  

  Decreases in clearance and protein binding, and increases in volume of distribution and half-life have been reported in patients with cirrhosis. In such patients, a 2- to 5- fold increase in mean half-life has been reported. Delayed elimination has also been reported for the active metabolite desmethyldiazepam. Benzodiazepines are commonly implicated in hepatic encephalopathy. Increases in half-life have also been reported in hepatic fibrosis and in both acute and chronic hepatitis (see  CLINICAL PHARMACOLOGY: Pharmacokinetics in Special Populations: Hepatic Insufficiency  ).

</Section>
    <Section id="S4" name="warnings">   WARNINGS

  Concomitant use of benzodiazepiones, including Valium, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.

 Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe Valium concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of Valium than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking Valium, prescribe a lower initial dose of the opioid and titrate based upon clinical response.

 Advise both patients and caregivers about the risks of respiratory depression and sedation when Valium is used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see   Drug Interactions    ).

 Valium is not recommended in the treatment of psychotic patients and should not be employed instead of appropriate treatment.

 Since Valium has a central nervous system depressant effect, patients should be advised against the simultaneous ingestion of alcohol and other CNS-depressant drugs during Valium therapy.

 As with other agents that have anticonvulsant activity, when Valium is used as an adjunct in treating convulsive disorders, the possibility of an increase in the frequency and/or severity of grand mal seizures may require an increase in the dosage of standard anticonvulsant medication. Abrupt withdrawal of Valium in such cases may also be associated with a temporary increase in the frequency and/or severity of seizures.

    Pregnancy

  An increased risk of congenital malformations and other developmental abnormalities associated with the use of benzodiazepine drugs during pregnancy has been suggested. There may also be non-teratogenic risks associated with the use of benzodiazepines during pregnancy. There have been reports of neonatal flaccidity, respiratory and feeding difficulties, and hypothermia in children born to mothers who have been receiving benzodiazepines late in pregnancy. In addition, children born to mothers receiving benzodiazepines on a regular basis late in pregnancy may be at some risk of experiencing withdrawal symptoms during the postnatal period.

 Diazepam has been shown to be teratogenic in mice and hamsters when given orally at daily doses of 100 mg/kg or greater (approximately eight times the maximum recommended human dose [MRHD=1 mg/kg/day] or greater on a mg/m  2  basis). Cleft palate and encephalopathy are the most common and consistently reported malformations produced in these species by administration of high, maternally toxic doses of diazepam during organogenesis. Rodent studies have indicated that prenatal exposure to diazepam doses similar to those used clinically can produce long-term changes in cellular immune responses, brain neurochemistry, and behavior.

 In general, the use of diazepam in women of childbearing potential, and more specifically during known pregnancy, should be considered only when the clinical situation warrants the risk to the fetus. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Patients should also be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physician about the desirability of discontinuing the drug.

    Labor and Delivery

  Special care must be taken when Valium is used during labor and delivery, as high single doses may produce irregularities in the fetal heart rate and hypotonia, poor sucking, hypothermia, and moderate respiratory depression in the neonates. With newborn infants it must be remembered that the enzyme system involved in the breakdown of the drug is not yet fully developed (especially in premature infants).

    Nursing Mothers

  Diazepam passes into breast milk. Breastfeeding is therefore not recommended in patients receiving Valium.

</Section>
  </Text>
  <IgnoredRegions>
    <IgnoredRegion len="21" name="heading" section="S1" start="2" />
    <IgnoredRegion len="11" name="heading" section="S3" start="3" />
    <IgnoredRegion len="8" name="heading" section="S4" start="3" />
    <IgnoredRegion len="7" name="heading" section="S3" start="19" />
    <IgnoredRegion len="52" name="heading" section="S2" start="73" />
    <IgnoredRegion len="27" name="heading" section="S1" start="161" />
    <IgnoredRegion len="28" name="heading" section="S1" start="273" />
    <IgnoredRegion len="19" name="heading" section="S1" start="361" />
    <IgnoredRegion len="26" name="heading" section="S1" start="424" />
    <IgnoredRegion len="42" name="heading" section="S1" start="470" />
    <IgnoredRegion len="22" name="heading" section="S1" start="972" />
    <IgnoredRegion len="24" name="heading" section="S1" start="1053" />
    <IgnoredRegion len="17" name="heading" section="S1" start="1100" />
    <IgnoredRegion len="10" name="heading" section="S1" start="1173" />
    <IgnoredRegion len="24" name="heading" section="S3" start="1575" />
    <IgnoredRegion len="24" name="heading" section="S1" start="1722" />
    <IgnoredRegion len="46" name="heading" section="S1" start="1750" />
    <IgnoredRegion len="9" name="heading" section="S4" start="2088" />
    <IgnoredRegion len="20" name="heading" section="S3" start="2378" />
    <IgnoredRegion len="7" name="heading" section="S3" start="2403" />
    <IgnoredRegion len="23" name="heading" section="S3" start="2984" />
    <IgnoredRegion len="7" name="heading" section="S3" start="3468" />
    <IgnoredRegion len="8" name="heading" section="S3" start="3575" />
    <IgnoredRegion len="47" name="heading" section="S3" start="3988" />
    <IgnoredRegion len="18" name="heading" section="S4" start="4089" />
    <IgnoredRegion len="9" name="heading" section="S3" start="4445" />
    <IgnoredRegion len="15" name="heading" section="S4" start="4523" />
    <IgnoredRegion len="52" name="heading" section="S3" start="4562" />
    <IgnoredRegion len="12" name="heading" section="S3" start="5492" />
    <IgnoredRegion len="16" name="heading" section="S3" start="5556" />
    <IgnoredRegion len="16" name="heading" section="S3" start="5681" />
    <IgnoredRegion len="24" name="heading" section="S3" start="6465" />
  </IgnoredRegions>
  <Mentions>
    <Mention id="M1" len="10" reason="from_drug_use" section="S1" start="68" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drowsiness" meddra_llt_id="10013649" meddra_pt="Somnolence" meddra_pt_id="10041349" />
    </Mention>
    <Mention id="M2" len="7" reason="from_drug_use" section="S1" start="80" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fatigue" meddra_llt_id="10016256" meddra_pt="Fatigue" meddra_pt_id="10016256" />
    </Mention>
    <Mention id="M3" len="15" reason="from_drug_use" section="S1" start="89" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle weakness" meddra_llt_id="10028350" meddra_pt="Muscular weakness" meddra_pt_id="10028372" />
    </Mention>
    <Mention id="M4" len="6" reason="from_drug_use" section="S1" start="110" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ataxia" meddra_llt_id="10003591" meddra_pt="Ataxia" meddra_pt_id="10003591" />
    </Mention>
    <Mention id="M5" len="9" reason="from_drug_use" section="S1" start="192" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Confusion" meddra_llt_id="10010300" meddra_pt="Confusional state" meddra_pt_id="10010305" />
    </Mention>
    <Mention id="M6" len="10" reason="from_drug_use" section="S1" start="203" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M7" len="10" reason="from_drug_use" section="S1" start="215" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dysarthria" meddra_llt_id="10013887" meddra_pt="Dysarthria" meddra_pt_id="10013887" />
    </Mention>
    <Mention id="M8" len="8" reason="from_drug_use" section="S1" start="227" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Headache" meddra_llt_id="10019211" meddra_pt="Headache" meddra_pt_id="10019211" />
    </Mention>
    <Mention id="M9" len="14" reason="from_drug_use" section="S1" start="237" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Speech slurred" meddra_llt_id="10041472" meddra_pt="Dysarthria" meddra_pt_id="10013887" />
    </Mention>
    <Mention id="M10" len="6" reason="from_drug_use" section="S1" start="253" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Tremor" meddra_llt_id="10044565" meddra_pt="Tremor" meddra_pt_id="10044565" />
    </Mention>
    <Mention id="M11" len="7" reason="from_drug_use" section="S1" start="261" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vertigo" meddra_llt_id="10047340" meddra_pt="Vertigo" meddra_pt_id="10047340" />
    </Mention>
    <Mention id="M12" len="12" reason="from_drug_use" section="S1" start="305" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Constipation" meddra_llt_id="10010774" meddra_pt="Constipation" meddra_pt_id="10010774" />
    </Mention>
    <Mention id="M13" len="6" reason="from_drug_use" section="S1" start="319" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nausea" meddra_llt_id="10028813" meddra_pt="Nausea" meddra_pt_id="10028813" />
    </Mention>
    <Mention id="M14" len="29" reason="from_drug_use" section="S1" start="327" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder gastrointestinal" meddra_llt_id="10013225" meddra_pt="Gastrointestinal disorder" meddra_pt_id="10017944" />
    </Mention>
    <Mention id="M15" len="14" reason="from_drug_use" section="S1" start="384" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Vision blurred" meddra_llt_id="10047513" meddra_pt="Vision blurred" meddra_pt_id="10047513" />
    </Mention>
    <Mention id="M16" len="8" reason="from_drug_use" section="S1" start="400" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Diplopia" meddra_llt_id="10013036" meddra_pt="Diplopia" meddra_pt_id="10013036" />
    </Mention>
    <Mention id="M17" len="9" reason="from_drug_use" section="S1" start="410" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dizziness" meddra_llt_id="10013573" meddra_pt="Dizziness" meddra_pt_id="10013573" />
    </Mention>
    <Mention id="M18" len="11" reason="from_drug_use" section="S1" start="454" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypotension" meddra_llt_id="10021097" meddra_pt="Hypotension" meddra_pt_id="10021097" />
    </Mention>
    <Mention id="M19" len="11" reason="from_drug_use" section="S1" start="516" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psychomotor hyperactivity" meddra_llt_id="10037211" meddra_pt="Psychomotor hyperactivity" meddra_pt_id="10037211" />
    </Mention>
    <Mention id="M20" len="12" reason="from_drug_use" section="S1" start="529" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Restlessness" meddra_llt_id="10038743" meddra_pt="Restlessness" meddra_pt_id="10038743" />
    </Mention>
    <Mention id="M50" len="25" reason="from_drug_use" section="S1" start="543" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psychomotor hyperactivity" meddra_llt_id="10037211" meddra_pt="Psychomotor hyperactivity" meddra_pt_id="10037211" />
    </Mention>
    <Mention id="M21" len="7" reason="from_drug_use" section="S1" start="570" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anxiety" meddra_llt_id="10002855" meddra_pt="Anxiety" meddra_pt_id="10002855" />
    </Mention>
    <Mention id="M22" len="9" reason="from_drug_use" section="S1" start="579" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Agitation" meddra_llt_id="10001497" meddra_pt="Agitation" meddra_pt_id="10001497" />
    </Mention>
    <Mention id="M23" len="14" reason="from_drug_use" section="S1" start="590" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Aggressiveness" meddra_llt_id="10001494" meddra_pt="Aggression" meddra_pt_id="10001488" />
    </Mention>
    <Mention id="M24" len="12" reason="from_drug_use" section="S1" start="606" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Irritability" meddra_llt_id="10022998" meddra_pt="Irritability" meddra_pt_id="10022998" />
    </Mention>
    <Mention id="M25" len="4" reason="from_drug_use" section="S1" start="620" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Rage" meddra_llt_id="10037804" meddra_pt="Anger" meddra_pt_id="10002368" />
    </Mention>
    <Mention id="M26" len="14" reason="from_drug_use" section="S1" start="626" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hallucinations" meddra_llt_id="10019077" meddra_pt="Hallucination" meddra_pt_id="10019063" />
    </Mention>
    <Mention id="M27" len="9" reason="from_drug_use" section="S1" start="642" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Other nonorganic psychoses" meddra_llt_id="10032314" meddra_pt="Psychotic disorder" meddra_pt_id="10061920" />
    </Mention>
    <Mention id="M28" len="9" reason="from_drug_use" section="S1" start="653" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Delusions" meddra_llt_id="10012260" meddra_pt="Delusion" meddra_pt_id="10012239" />
    </Mention>
    <Mention id="M29" len="27" reason="from_drug_use" section="S1" start="664" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Muscle spasticity" meddra_llt_id="10028335" meddra_pt="Muscle spasticity" meddra_pt_id="10028335" />
    </Mention>
    <Mention id="M30" len="8" reason="from_drug_use" section="S1" start="693" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Insomnia" meddra_llt_id="10022437" meddra_pt="Insomnia" meddra_pt_id="10022437" />
    </Mention>
    <Mention id="M31" len="18" reason="from_drug_use" section="S1" start="703" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Sleep disturbances" meddra_llt_id="10040997" meddra_pt="Sleep disorder" meddra_pt_id="10040984" />
    </Mention>
    <Mention id="M32" len="10" reason="from_drug_use" section="S1" start="727" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Nightmares" meddra_llt_id="10029414" meddra_pt="Nightmare" meddra_pt_id="10029412" />
    </Mention>
    <Mention id="M51" len="22" reason="from_drug_use" section="S1" start="739" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder behavior" meddra_llt_id="10013190" meddra_pt="Abnormal behaviour" meddra_pt_id="10061422" />
    </Mention>
    <Mention id="M52" len="26" reason="from_drug_use" section="S1" start="772" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Behavior abnormal" meddra_llt_id="10004203" meddra_pt="Abnormal behaviour" meddra_pt_id="10061422" />
    </Mention>
    <Mention id="M33" len="12" reason="from_drug_use" section="S1" start="998" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Incontinence" meddra_llt_id="10021639" meddra_pt="Incontinence" meddra_pt_id="10021639" />
    </Mention>
    <Mention id="M34" len="17" reason="from_drug_use" section="S1" start="1012" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Libido disorder" meddra_llt_id="10061221" meddra_pt="Libido disorder" meddra_pt_id="10061221" />
    </Mention>
    <Mention id="M35" len="17" reason="from_drug_use" section="S1" start="1031" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Urinary retention" meddra_llt_id="10046555" meddra_pt="Urinary retention" meddra_pt_id="10046555" />
    </Mention>
    <Mention id="M36" len="14" reason="from_drug_use" section="S1" start="1081" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Reaction skin" meddra_llt_id="10037971" meddra_pt="Skin reaction" meddra_pt_id="10040914" />
      <Normalization meddra_pt="Skin toxicity" meddra_pt_id="10059516" />
    </Mention>
    <Mention id="M37" len="22" reason="from_drug_use" section="S1" start="1121" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Transaminases increased" meddra_llt_id="10054889" meddra_pt="Transaminases increased" meddra_pt_id="10054889" />
    </Mention>
    <Mention id="M38" len="8,20" reason="from_drug_use" section="S1" start="1121,1148" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Serum alkaline phosphatase elevated" meddra_llt_id="10040133" meddra_pt="Blood alkaline phosphatase increased" meddra_pt_id="10059570" />
    </Mention>
    <Mention id="M39" len="21" reason="from_drug_use" section="S1" start="1187" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Altered saliva" meddra_llt_id="10001852" meddra_pt="Saliva altered" meddra_pt_id="10039379" />
    </Mention>
    <Mention id="M40" len="9" reason="from_drug_use" section="S1" start="1220" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Dry mouth" meddra_llt_id="10013781" meddra_pt="Dry mouth" meddra_pt_id="10013781" />
    </Mention>
    <Mention id="M41" len="15" reason="from_drug_use" section="S1" start="1231" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypersalivation" meddra_llt_id="10020746" meddra_pt="Salivary hypersecretion" meddra_pt_id="10039424" />
    </Mention>
    <Mention id="M42" len="17" reason="from_drug_use" section="S1" start="1249" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anterograde amnesia" meddra_llt_id="10002711" meddra_pt="Anterograde amnesia" meddra_pt_id="10002711" />
    </Mention>
    <Mention id="M43" len="16" reason="from_drug_use" section="S1" start="1343" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Amnesia" meddra_llt_id="10001949" meddra_pt="Amnesia" meddra_pt_id="10001949" />
    </Mention>
    <Mention id="M44" len="22" reason="from_drug_use" section="S1" start="1383" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Disorder behavior" meddra_llt_id="10013190" meddra_pt="Abnormal behaviour" meddra_pt_id="10061422" />
    </Mention>
    <Mention id="M45" len="14" reason="from_drug_use" section="S1" start="1415" type="OSE_Labeled_AE">
      <Normalization meddra_llt="EEG abnormal" meddra_llt_id="10014276" meddra_pt="Electroencephalogram abnormal" meddra_pt_id="10014408" />
    </Mention>
    <Mention id="M46" len="11" reason="from_drug_use" section="S1" start="1605" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neutropenia" meddra_llt_id="10029354" meddra_pt="Neutropenia" meddra_pt_id="10029354" />
    </Mention>
    <Mention id="M47" len="8" reason="from_drug_use" section="S1" start="1621" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Jaundice" meddra_llt_id="10023126" meddra_pt="Jaundice" meddra_pt_id="10023126" />
    </Mention>
    <Mention id="M48" len="5" reason="class_effect" section="S1" start="1827" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fall" meddra_llt_id="10016173" meddra_pt="Fall" meddra_pt_id="10016173" />
    </Mention>
    <Mention id="M49" len="9" reason="class_effect" section="S1" start="1837" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Ill-defined fractures of bones of trunk" meddra_llt_id="10021350" meddra_pt="Fracture" meddra_pt_id="10017076" />
    </Mention>
    <Mention id="M53" len="8" reason="AE_from_drug_interaction" section="S2" start="199" type="NonOSE_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M54" len="22" reason="AE_from_drug_interaction" section="S2" start="209" type="NonOSE_AE">
      <Normalization meddra_llt="Depression respiratory" meddra_llt_id="10012396" meddra_pt="Respiratory depression" meddra_pt_id="10038678" />
    </Mention>
    <Mention id="M55" len="4" reason="AE_from_drug_interaction" section="S2" start="233" type="NonOSE_AE">
      <Normalization meddra_llt="Coma" meddra_llt_id="10010071" meddra_pt="Coma" meddra_pt_id="10010071" />
    </Mention>
    <Mention id="M58" len="5" reason="general_term" section="S2" start="243" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M56" len="22" reason="AE_only_as_instruction" section="S2" start="514" type="NonOSE_AE">
      <Normalization meddra_llt="Depression respiratory" meddra_llt_id="10012396" meddra_pt="Respiratory depression" meddra_pt_id="10038678" />
    </Mention>
    <Mention id="M57" len="8" reason="AE_only_as_instruction" section="S2" start="541" type="NonOSE_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M63" len="9" reason="preexisting_condition_or_risk_factor" section="S3" start="450" type="Not_AE_Candidate">
      <Normalization meddra_llt="Depressed state" meddra_llt_id="10012377" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M59" len="10" reason="preexisting_condition_or_risk_factor" section="S3" start="518" type="Not_AE_Candidate">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M64" len="7,15" reason="preexisting_condition_or_risk_factor" section="S3" start="532,551" type="Not_AE_Candidate">
      <Normalization meddra_llt="Anxiety/depression" meddra_llt_id="10002872" meddra_pt="Depression" meddra_pt_id="10012378" />
    </Mention>
    <Mention id="M60" len="19" reason="preexisting_condition_or_risk_factor" section="S3" start="602" type="Not_AE_Candidate">
      <Normalization meddra_llt="Suicidal tendency" meddra_llt_id="10042461" meddra_pt="Suicidal ideation" meddra_pt_id="10042458" />
    </Mention>
    <Mention id="M93" len="11,9" reason="class_effect" section="S3" start="681,709" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Psychiatric symptom" meddra_llt_id="10061472" meddra_pt="Psychiatric symptom" meddra_pt_id="10061472" />
      <Normalization meddra_pt="Mental disorder" meddra_pt_id="10061284" />
    </Mention>
    <Mention id="M94" len="21" reason="class_effect" section="S3" start="697" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Paradoxical drug reaction" meddra_llt_id="10048958" meddra_pt="Paradoxical drug reaction" meddra_pt_id="10048958" />
    </Mention>
    <Mention id="M65" len="33" reason="preexisting_condition_or_risk_factor" section="S3" start="970" type="Not_AE_Candidate">
      <Normalization meddra_llt="Respiratory insufficiency" meddra_llt_id="10038701" meddra_pt="Respiratory failure" meddra_pt_id="10038695" />
    </Mention>
    <Mention id="M85" len="22" reason="AE_only_as_instruction" section="S3" start="1024" type="NonOSE_AE">
      <Normalization meddra_llt="Depression respiratory" meddra_llt_id="10012396" meddra_pt="Respiratory depression" meddra_pt_id="10038678" />
    </Mention>
    <Mention id="M66" len="7,5" reason="preexisting_condition_or_risk_factor" section="S3" start="1132,1148" type="Not_AE_Candidate">
      <Normalization meddra_llt="Alcohol abuse" meddra_llt_id="10001584" meddra_pt="Alcohol abuse" meddra_pt_id="10001584" />
    </Mention>
    <Mention id="M67" len="10" reason="preexisting_condition_or_risk_factor" section="S3" start="1143" type="Not_AE_Candidate">
      <Normalization meddra_llt="Drug abuse" meddra_llt_id="10013654" meddra_pt="Drug abuse" meddra_pt_id="10013654" />
      <Normalization meddra_pt="Substance abuse" meddra_pt_id="10066169" />
    </Mention>
    <Mention id="M68" len="11" reason="preexisting_condition_or_risk_factor" section="S3" start="1195" type="Not_AE_Candidate">
      <Normalization meddra_llt="Debility" meddra_llt_id="10011942" meddra_pt="Asthenia" meddra_pt_id="10003549" />
    </Mention>
    <Mention id="M73" len="6" reason="AE_only_as_instruction" section="S3" start="1326" type="NonOSE_AE">
      <Normalization meddra_llt="Ataxia" meddra_llt_id="10003591" meddra_pt="Ataxia" meddra_pt_id="10003591" />
    </Mention>
    <Mention id="M74" len="12" reason="AE_only_as_instruction" section="S3" start="1336" type="NonOSE_AE">
      <Normalization meddra_llt="Oversedation" meddra_llt_id="10033305" meddra_pt="Sedation complication" meddra_pt_id="10079741" />
    </Mention>
    <Mention id="M95" len="31" reason="class_effect" section="S3" start="1456" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Drug tolerance" meddra_llt_id="10052804" meddra_pt="Drug tolerance" meddra_pt_id="10052804" />
    </Mention>
    <Mention id="M75" len="22" reason="AE_from_drug_interaction" section="S3" start="2487" type="NonOSE_AE">
      <Normalization meddra_llt="Depression respiratory" meddra_llt_id="10012396" meddra_pt="Respiratory depression" meddra_pt_id="10038678" />
    </Mention>
    <Mention id="M76" len="22" reason="AE_from_drug_interaction" section="S3" start="2801" type="NonOSE_AE">
      <Normalization meddra_llt="Depression respiratory" meddra_llt_id="10012396" meddra_pt="Respiratory depression" meddra_pt_id="10038678" />
    </Mention>
    <Mention id="M77" len="22" reason="AE_only_as_instruction" section="S3" start="2942" type="NonOSE_AE">
      <Normalization meddra_llt="Depression respiratory" meddra_llt_id="10012396" meddra_pt="Respiratory depression" meddra_pt_id="10038678" />
    </Mention>
    <Mention id="M78" len="8" reason="AE_only_as_instruction" section="S3" start="2969" type="NonOSE_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M91" len="34" reason="AE_from_drug_interaction" section="S3" start="3534" type="NonOSE_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M86" len="8" reason="AE_from_drug_interaction" section="S3" start="4314" type="NonOSE_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M79" len="12" reason="AE_animal" section="S3" start="4899" type="NonOSE_AE">
      <Normalization meddra_llt="Tumor liver" meddra_llt_id="10045151" meddra_pt="Hepatic neoplasm" meddra_pt_id="10019695" />
    </Mention>
    <Mention id="M87" len="9" reason="AE_only_as_instruction" section="S3" start="5012" type="NonOSE_AE">
      <Normalization meddra_llt="Mutagenic effect" meddra_llt_id="10028400" meddra_pt="Mutagenic effect" meddra_pt_id="10028400" />
    </Mention>
    <Mention id="M80" len="38" reason="AE_animal" section="S3" start="5081" type="NonOSE_AE">
      <Normalization meddra_llt="Fertility decreased female" meddra_llt_id="10016463" meddra_pt="Infertility female" meddra_pt_id="10021928" />
    </Mention>
    <Mention id="M81" len="26,19" reason="AE_animal" section="S3" start="5081,5141" type="NonOSE_AE">
      <Normalization meddra_llt="Death neonatal" meddra_llt_id="10011912" meddra_pt="Death neonatal" meddra_pt_id="10011912" />
    </Mention>
    <Mention id="M88" len="9" reason="negation" section="S3" start="5362" type="NonOSE_AE">
      <Normalization meddra_llt="Fertility investigations" meddra_llt_id="10016469" meddra_pt="Infertility tests" meddra_pt_id="10021931" />
    </Mention>
    <Mention id="M89" len="19" reason="negation" section="S3" start="5375" type="NonOSE_AE">
      <Normalization meddra_llt="Unevaluable investigation" meddra_llt_id="10070435" meddra_pt="Unevaluable investigation" meddra_pt_id="10070435" />
    </Mention>
    <Mention id="M90" len="9" reason="AE_only_as_instruction" section="S3" start="5537" type="NonOSE_AE">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M82" len="6" reason="AE_only_as_instruction" section="S3" start="5831" type="NonOSE_AE">
      <Normalization meddra_llt="Ataxia" meddra_llt_id="10003591" meddra_pt="Ataxia" meddra_pt_id="10003591" />
    </Mention>
    <Mention id="M83" len="12" reason="AE_only_as_instruction" section="S3" start="5841" type="NonOSE_AE">
      <Normalization meddra_llt="Oversedation" meddra_llt_id="10033305" meddra_pt="Sedation complication" meddra_pt_id="10079741" />
    </Mention>
    <Mention id="M84" len="15" reason="general_term" section="S3" start="6224" type="NonOSE_AE">
      <Normalization meddra_llt="Toxic reaction (NOS)" meddra_llt_id="10044247" meddra_pt="Toxicity to various agents" meddra_pt_id="10070863" />
      <Normalization meddra_pt="Adverse reaction" meddra_pt_id="10067484" />
    </Mention>
    <Mention id="M61" len="23" reason="preexisting_condition_or_risk_factor" section="S3" start="6272" type="Not_AE_Candidate">
      <Normalization meddra_llt="Impaired renal function" meddra_llt_id="10021523" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M69" len="24" reason="preexisting_condition_or_risk_factor" section="S3" start="6346" type="Not_AE_Candidate">
      <Normalization meddra_llt="Impaired renal function" meddra_llt_id="10021523" meddra_pt="Renal impairment" meddra_pt_id="10062237" />
    </Mention>
    <Mention id="M70" len="9" reason="preexisting_condition_or_risk_factor" section="S3" start="6627" type="Not_AE_Candidate">
      <Normalization meddra_llt="Micronodular cirrhosis" meddra_llt_id="10079256" meddra_pt="Hepatic cirrhosis" meddra_pt_id="10019641" />
    </Mention>
    <Mention id="M92" len="22" reason="class_effect" section="S3" start="6849" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hepatic encephalopathy" meddra_llt_id="10019660" meddra_pt="Hepatic encephalopathy" meddra_pt_id="10019660" />
    </Mention>
    <Mention id="M62" len="16" reason="preexisting_condition_or_risk_factor" section="S3" start="6923" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hepatic fibrosis" meddra_llt_id="10019668" meddra_pt="Hepatic fibrosis" meddra_pt_id="10019668" />
    </Mention>
    <Mention id="M72" len="5,9" reason="preexisting_condition_or_risk_factor" section="S3" start="6952,6970" type="Not_AE_Candidate">
      <Normalization meddra_llt="Hepatitis acute" meddra_llt_id="10019727" meddra_pt="Hepatitis acute" meddra_pt_id="10019727" />
    </Mention>
    <Mention id="M71" len="17" reason="preexisting_condition_or_risk_factor" section="S3" start="6962" type="Not_AE_Candidate">
      <Normalization meddra_llt="Chronic hepatitis" meddra_llt_id="10008909" meddra_pt="Chronic hepatitis" meddra_pt_id="10008909" />
    </Mention>
    <Mention id="M106" len="8" reason="AE_from_drug_interaction" section="S4" start="105" type="NonOSE_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M107" len="22" reason="AE_from_drug_interaction" section="S4" start="115" type="NonOSE_AE">
      <Normalization meddra_llt="Depression respiratory" meddra_llt_id="10012396" meddra_pt="Respiratory depression" meddra_pt_id="10038678" />
    </Mention>
    <Mention id="M108" len="4" reason="AE_from_drug_interaction" section="S4" start="139" type="NonOSE_AE">
      <Normalization meddra_llt="Coma" meddra_llt_id="10010071" meddra_pt="Coma" meddra_pt_id="10010071" />
    </Mention>
    <Mention id="M119" len="5" reason="general_term" section="S4" start="149" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M120" len="9" reason="general_term" section="S4" start="441" type="NonOSE_AE">
      <Normalization meddra_llt="Death" meddra_llt_id="10011906" meddra_pt="Death" meddra_pt_id="10011906" />
    </Mention>
    <Mention id="M109" len="22" reason="AE_only_as_instruction" section="S4" start="690" type="NonOSE_AE">
      <Normalization meddra_llt="Depression respiratory" meddra_llt_id="10012396" meddra_pt="Respiratory depression" meddra_pt_id="10038678" />
    </Mention>
    <Mention id="M110" len="8" reason="AE_only_as_instruction" section="S4" start="717" type="NonOSE_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M111" len="22" reason="AE_only_as_instruction" section="S4" start="1108" type="NonOSE_AE">
      <Normalization meddra_llt="Depression respiratory" meddra_llt_id="10012396" meddra_pt="Respiratory depression" meddra_pt_id="10038678" />
    </Mention>
    <Mention id="M112" len="8" reason="AE_only_as_instruction" section="S4" start="1135" type="NonOSE_AE">
      <Normalization meddra_llt="Sedation" meddra_llt_id="10039897" meddra_pt="Sedation" meddra_pt_id="10039897" />
    </Mention>
    <Mention id="M96" len="9" reason="preexisting_condition_or_risk_factor" section="S4" start="1387" type="Not_AE_Candidate">
      <Normalization meddra_llt="Psychotic" meddra_llt_id="10037248" meddra_pt="Psychotic disorder" meddra_pt_id="10061920" />
    </Mention>
    <Mention id="M130" len="40" reason="from_drug_use" section="S4" start="1488" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Depressed level of consciousness" meddra_llt_id="10012373" meddra_pt="Depressed level of consciousness" meddra_pt_id="10012373" />
    </Mention>
    <Mention id="M97" len="20" reason="indication" section="S4" start="1761" type="Not_AE_Candidate">
      <Normalization meddra_llt="Convulsive disorder" meddra_llt_id="10010924" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M104" len="18" reason="preexisting_condition_or_risk_factor" section="S4" start="1850" type="Not_AE_Candidate">
      <Normalization meddra_llt="Grand mal" meddra_llt_id="10018658" meddra_pt="Generalised tonic-clonic seizure" meddra_pt_id="10018100" />
    </Mention>
    <Mention id="M121" len="8" reason="OD_or_withdrawal" section="S4" start="2073" type="NonOSE_AE">
      <Normalization meddra_llt="Seizures" meddra_llt_id="10039910" meddra_pt="Seizure" meddra_pt_id="10039906" />
    </Mention>
    <Mention id="M127" len="23" reason="class_effect" section="S4" start="2122" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Congenital anomaly in offspring" meddra_llt_id="10063726" meddra_pt="Congenital anomaly in offspring" meddra_pt_id="10063726" />
      <Normalization meddra_pt="Congenital anomaly" meddra_pt_id="10010356" />
    </Mention>
    <Mention id="M128" len="27" reason="class_effect" section="S4" start="2157" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Anomaly anomaly congen" meddra_llt_id="10002614" meddra_pt="Congenital anomaly" meddra_pt_id="10010356" />
      <Normalization meddra_pt="Congenital anomaly in offspring" meddra_pt_id="10063726" />
    </Mention>
    <Mention id="M98" len="9" reason="preexisting_condition_or_risk_factor" section="S4" start="2240" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M137" len="21" reason="class_effect" section="S4" start="2288" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Maternal drugs affecting fetus" meddra_llt_id="10060521" meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
      <Normalization meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
    </Mention>
    <Mention id="M99" len="9" reason="preexisting_condition_or_risk_factor" section="S4" start="2360" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M131" len="19" reason="class_effect" section="S4" start="2398" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypotonia neonatal" meddra_llt_id="10021119" meddra_pt="Hypotonia neonatal" meddra_pt_id="10021119" />
    </Mention>
    <Mention id="M140" len="8,11" reason="class_effect" section="S4" start="2398,2461" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypothermia neonatal" meddra_llt_id="10050080" meddra_pt="Hypothermia neonatal" meddra_pt_id="10050080" />
    </Mention>
    <Mention id="M141" len="8,11,12" reason="class_effect" section="S4" start="2398,2419,2443" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Respiratory disorder neonatal" meddra_llt_id="10061484" meddra_pt="Respiratory disorder neonatal" meddra_pt_id="10061484" />
    </Mention>
    <Mention id="M142" len="8,20" reason="class_effect" section="S4" start="2398,2435" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Poor feeding neonatal" meddra_llt_id="10075318" meddra_pt="Poor feeding infant" meddra_pt_id="10075316" />
    </Mention>
    <Mention id="M100" len="9" reason="preexisting_condition_or_risk_factor" section="S4" start="2549" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M101" len="9" reason="preexisting_condition_or_risk_factor" section="S4" start="2651" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M132" len="19,9" reason="class_effect" section="S4" start="2697,2728" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Withdrawal syndrome neonatal" meddra_llt_id="10048012" meddra_pt="Drug withdrawal syndrome neonatal" meddra_pt_id="10013756" />
    </Mention>
    <Mention id="M122" len="11" reason="AE_animal" section="S4" start="2778" type="NonOSE_AE">
      <Normalization meddra_llt="Teratogenicity" meddra_llt_id="10043275" meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M113" len="12" reason="AE_animal" section="S4" start="2982" type="NonOSE_AE">
      <Normalization meddra_llt="Cleft palate" meddra_llt_id="10009269" meddra_pt="Cleft palate" meddra_pt_id="10009269" />
    </Mention>
    <Mention id="M114" len="14" reason="AE_animal" section="S4" start="2999" type="NonOSE_AE">
      <Normalization meddra_llt="Encephalopathy" meddra_llt_id="10014625" meddra_pt="Encephalopathy" meddra_pt_id="10014625" />
    </Mention>
    <Mention id="M115" len="13" reason="AE_animal" section="S4" start="3060" type="NonOSE_AE">
      <Normalization meddra_llt="Congenital anomaly in offspring" meddra_llt_id="10063726" meddra_pt="Congenital anomaly in offspring" meddra_pt_id="10063726" />
      <Normalization meddra_pt="Congenital anomaly" meddra_pt_id="10010356" />
    </Mention>
    <Mention id="M116" len="36" reason="AE_animal" section="S4" start="3310" type="NonOSE_AE">
      <Normalization meddra_llt="Immune disorder (NOS)" meddra_llt_id="10021418" meddra_pt="Immune system disorder" meddra_pt_id="10021425" />
    </Mention>
    <Mention id="M117" len="10,20" reason="AE_animal" section="S4" start="3310,3348" type="NonOSE_AE">
      <Normalization meddra_llt="Nervous system disorder" meddra_llt_id="10029202" meddra_pt="Nervous system disorder" meddra_pt_id="10029202" />
      <Normalization meddra_pt="Neurotoxicity" meddra_pt_id="10029350" />
      <Normalization meddra_pt="Neurological symptom" meddra_pt_id="10060860" />
    </Mention>
    <Mention id="M118" len="10,8" reason="AE_animal" section="S4" start="3310,3374" type="NonOSE_AE">
      <Normalization meddra_llt="Disorder behavior" meddra_llt_id="10013190" meddra_pt="Abnormal behaviour" meddra_pt_id="10061422" />
    </Mention>
    <Mention id="M102" len="9" reason="preexisting_condition_or_risk_factor" section="S4" start="3489" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M138" len="17" reason="from_drug_use" section="S4" start="3567" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Teratogenicity" meddra_llt_id="10043275" meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M123" len="8" reason="AE_only_as_instruction" section="S4" start="3648" type="NonOSE_AE">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M105" len="9" reason="preexisting_condition_or_risk_factor" section="S4" start="3745" type="Not_AE_Candidate">
      <Normalization meddra_llt="Pregnancy" meddra_llt_id="10036556" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M124" len="8" reason="AE_only_as_instruction" section="S4" start="3782" type="NonOSE_AE">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M139" len="19" reason="from_drug_use" section="S4" start="3863" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fetal damage" meddra_llt_id="10054743" meddra_pt="Foetal damage" meddra_pt_id="10016852" />
      <Normalization meddra_pt="Teratogenicity" meddra_pt_id="10043275" />
      <Normalization meddra_pt="Maternal drugs affecting foetus" meddra_pt_id="10026923" />
    </Mention>
    <Mention id="M125" len="8" reason="AE_only_as_instruction" section="S4" start="3936" type="NonOSE_AE">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M126" len="8" reason="AE_only_as_instruction" section="S4" start="3980" type="NonOSE_AE">
      <Normalization meddra_llt="Pregnant" meddra_llt_id="10036586" meddra_pt="Pregnancy" meddra_pt_id="10036556" />
    </Mention>
    <Mention id="M129" len="38" reason="from_drug_use" section="S4" start="4218" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Fetal heart rate disorder" meddra_llt_id="10054386" meddra_pt="Foetal heart rate disorder" meddra_pt_id="10061158" />
    </Mention>
    <Mention id="M133" len="9,8" reason="from_drug_use" section="S4" start="4261,4342" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypotonia neonatal" meddra_llt_id="10021119" meddra_pt="Hypotonia neonatal" meddra_pt_id="10021119" />
    </Mention>
    <Mention id="M134" len="12,8" reason="from_drug_use" section="S4" start="4272,4342" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Poor sucking reflex" meddra_llt_id="10058605" meddra_pt="Poor sucking reflex" meddra_pt_id="10058605" />
    </Mention>
    <Mention id="M135" len="11,8" reason="from_drug_use" section="S4" start="4286,4342" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Hypothermia neonatal" meddra_llt_id="10050080" meddra_pt="Hypothermia neonatal" meddra_pt_id="10050080" />
    </Mention>
    <Mention id="M136" len="38" reason="from_drug_use" section="S4" start="4312" type="OSE_Labeled_AE">
      <Normalization meddra_llt="Neonatal respiratory depression" meddra_llt_id="10028970" meddra_pt="Neonatal respiratory depression" meddra_pt_id="10028970" />
    </Mention>
    <Mention id="M103" len="17" reason="preexisting_condition_or_risk_factor" section="S4" start="4498" type="Not_AE_Candidate">
      <Normalization meddra_llt="Infant premature" meddra_llt_id="10021734" meddra_pt="Premature baby" meddra_pt_id="10036590" />
    </Mention>
  </Mentions>
</GoldLabel>